Preclinical studies have demonstrated that targeting OPN through monoclonal antibodies or small molecule inhibitors can effectively attenuate tumor growth and metastasis and improve the therapeutic efficacy of other cancer treatments. This evidence concerns the gene SPP1 and neoplasm.